TIGIT and neoplasm: The expression of immune-related checkpoints (PD-L1, LAG3, CTLA4, TIM3, and TIGIT) in our high-risk group was higher than in the low-risk group, but the MSI and TMB, which indirectly reflect the ability of a tumor to produce new antigens and predict the efficacy of immunotherapy for a variety of tumors, were not significantly different between the groups (Supplementary Figure S5).